Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B

Virology Journal

Volumn 10, Issue , 2013, Pages

  Zhang, Lin ^a   Hao, Chun Qiu ^b   Liu, Jiang Fu ^a   Wang, Meng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HBV; Lamivudine; Liver failure; Meta analysis; Severe hepatitis

Indexed keywords

BILIRUBIN; LAMIVUDINE; PROTHROMBIN; VIRUS DNA;

ARTICLE; BILIRUBIN BLOOD LEVEL; COCHRANE LIBRARY; DATA BASE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HUMAN; LIVER FAILURE; MEDLINE; META ANALYSIS; MORTALITY; RISK FACTOR; SHORT COURSE THERAPY; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

HEPATITIS B VIRUS; LETTUCE MOSAIC VIRUS;

EID: 84876787178     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-134     Document Type: Article

References (50)

1. Fulminant hepatic failure in an African setting: etiology, clinical course, and predictors of mortality. Mudawi HM, Yousif BA, Dig Dis Sci 2007 52 3266 3299 10.1007/s10620-006-9730-z 17436091 (Pubitemid 47512540)
2. Clinical features of fulminant hepatic failure in a tertiary hospital with a liver transplant center in Korea. Heo NY, Lim YS, Kang JM, Oh SI, Park CS, Jung SW, Lee YS, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ, Korean J Hepatol 2006 12 82 92 16565609
3. Etiologies of acute liver failure. Lee WM, Semin Liver Dis 2008 28 142 152 10.1055/s-2008-1073114 18452114 (Pubitemid 351632954)
4. Diagnostic and treatment guidelines for liver failure. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association, Zhonghua Ganzangbing Zazhi 2006 14 643 646 16995974
5. Fulminant viral hepatitis: molecular and cellular basis, and clinical implications. Liu M, Chan CW, McGilvray I, Ning Q, Levy GA, Expert Rev Mol Med 2001 2001 1 19 14987376
6. The systemic inflammatory response syndrome in acute liver failure. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R, Hepatology 2000 32 734 739 11003617
7. Proteome responses to stable hepatitis B virus transfection and following interferon alpha treatment in human liver cell line HepG2. Wang J, Jiang D, Zhang H, Lv S, Rao H, Fei R, Wei L, Proteomics 2009 9 1672 1682 10.1002/pmic.200800621 19242931
8. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, Ferrari C, J Hepatol 2003 39 595 605 10.1016/S0168-8278(03)00292-7 12971971 (Pubitemid 37204661)
9. The treatment of complications of liver failure. Gao ZL, Zhang XH, Zhonghua Ganzangbing Zazhi 2010 18 811 813 21138626
10. Treatment and prevention scheme of viral hepatitis. Chinese Medical Association, J Infec Dis 2001 19 56 62
11. Assessing the quality of reports of randomized clinical trialss blinding necessary? Jadad AR, Moor RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ, Controlled Clin Trials 1996 17 1 12 10.1016/0197-2456(95)00134-4 8721797 (Pubitemid 26120810)
12. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Ann Intern Med 2007 147 573 577 10.7326/0003-4819-147-8-200710160-00010 17938396 (Pubitemid 351664504)
13. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, Sulkowski MS, Goodman SN, JAMA 2001 285 193 199 10.1001/jama.285.2.193 11176813 (Pubitemid 32048522)
14. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC, J Gastroenterol Hepatol 2010 25 583 590 10.1111/j.1440-1746.2009.06089.x 19968744
15. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection associated with acute-on-chronic liver failure. Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, Tang H, Feng P, Dig Dis Sci 2010 55 2373 2380 10.1007/s10620-010-1257-7 20512414
16. Clinical research on lamivudine treatment for severe chronic hepatitis B. Mi LJ, Guo H, Jin GH, Clinical Focus 2009 24 534 535
17. Discussion on lamivudine treatment for severe chronic hepatitis B. Zhang P, Chin J Clin Hepatol 2008 24 291 292
18. Research on the prognosis of lamivudine treatment for severe chronic hepatitis B. Han YH, An P, Chin J Prac Inter Med 2007 27 692 693
19. Clinical observation on the short-term effect of lamivudine treatment for severe chronic hepatitis B. Yan DH, Zhao NF, Liang WF, Wu W, Chin J Clin Hepatol 2004 20 178 216
20. Clinical observation on the effectiveness of lamivudine treatment for severe chronic hepatitis B. He Y, Cheng N, Cheng XY, Jiangxi Med J 2005 40 640 642
21. Clinical observation on lamivudine treatment for severe chronic hepatitis B. Liao JH, J Guangdong Med College 2004 22 264 265
22. Clinical observation on the effectiveness of lamivudine treatment for severe chronic hepatitis B. Yuan J, Zhou BP, Hu YW, Ao FJ, Yang GL, Wen B, Liu Z, Ma WM, Chin J Infec Dis 2001 19 372 374
23. Observation on the effectiveness of lamivudine treatment for severe chronic hepatitis B. Zhang LQ, Liu CY, Shi BN, Wang WH, Chin J Microecol 2006 18 134
24. Observation on the effectiveness of lamivudine treatment for severe chronic hepatitis B. Zhan GQ, Zheng SJ, Deng WX, Zhu L, Li JK, Chin J Clin Hepatol 2006 22 425 426
25. Clinical observation on the effectiveness of lamivudine treatment for severe chronic hepatitis B. Cao L, Xu HF, Wang ZR, Chin J Hemorheol 2007 17 612 613
26. Clinical research on lamivudine treatment for severe chronic hepatitis B. Zhu GL, Zhong JP, Huang ZR, Fei YM, Shen HJ, Li SF, Zhou SY, Chen BC, Chinese Hepatology 2002 7 36 38
27. Clinical research on lamivudine treatment for severe chronic hepatitis B. Zhou BX, Li YK, Shang J, Yang YX, Clinical Focus 2003 18 690 691
28. Clinical research on lamivudine treatment for severe chronic hepatitis B. Guo JC, Ru RP, Ye WJ, He JJ, Chin J Modern Appl Pharm 2003 20 313 314
29. Observation on the short-term effect of lamivudine treatment for severe chronic hepatitis B. Zhong YB, Yu SK, J Gannan Med College 2007 27 846 847
30. Observation on the effectiveness of lamivudine treatment for severe chronic hepatitis B. Zhou XQ, Liu FB, J Clin Hepatol 2007 23 208 209
31. Observation on the effectiveness of lamivudine treatment for severe chronic hepatitis B. Ding FY, Jiang BH, Zang YX, Yang BH, Sun TL, Chin J Coal Ind Med 2003 6 72 73
32. Short-term effect of lamivudine treatment for severe chronic hepatitis B. Pan JZ, Zhejiang Journal of Clinical Medicine 2007 9 1330 1331
33. Reports on 30 cases of using lamivudine treatment for severe chronic hepatitis B. Wang Y, Huang YS, Journal of Chinese Physician 2003 5 275 276
34. Clinical observation on lamivudine treatment for severe chronic hepatitis B. Qin SJ, Wang JS, Clinical Focus 2003 18 942 943
35. Triple attack caused by hepatitis B associated liver failure. Ye YL, Gao ZL, Chinese Journal of Hepatology 2009 17 638 640 19719932
36. Spontaneous reactivation of chronic hepatitis B virus infection. Davies GL, Hoofnagle JH, Waggoner JG, Gastroenterology 1984 86 230 235 6690350 (Pubitemid 14218576)
37. Spontaneous reactivation of chronic hepatitis B: Patterns and natural history. Gupta S, Govindarajan S, Fong TL, Redeker AG, J Clin Gastroenterol 1990 12 562 568 10.1097/00004836-199010000-00015 2230000 (Pubitemid 20303420)
38. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Levy P, Marcellin P, Martinot-Peignoux M, Redeker AG, Hepatology 1990 12 570 574 10.1002/hep. 1840120320 2401462 (Pubitemid 20382025)
39. Analysis on the predisposing cause and outcome of 289 cases of hepatitis B patients complicated with chronic or acute liver failure. Zhao ZG, Han T, Gao YT, Gao YY, Zhang Y, Wu Z, World J Gastroenterol 2009 17 3269 3272
40. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Tsang SW, Chan HL, Leung NW, Chau TN, Lai ST, Chan FK, Sung JJ, Aliment Pharmacol Ther 2001 15 1737 1744 10.1046/j.1365-2036.2001.01107.x 11683687 (Pubitemid 33001137)
41. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. Chien RN, Lin CH, Liaw YF, Hepatol 2003 38 322 327
42. Antiviral therapy for hepatitis B virus associated hepatic failure. Wang YM, Tang YZ, Hepatobiliary Pancreat Dis Int 2009 8 17 24 19208509
43. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. Yu JW, Sun LJ, Zhao YH, Li SC, Gastroenterol Hepatol 2008 23 1242 1249 10.1111/j.1440-1746.2008.05484.x
44. Prognostic factors in severe exacerbation of chornic hepatitis B. Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong DK, Doutreloigne J, Bogaerts V, Wong BC, Fan ST, Lai CL, CID 2003 36 978 984
45. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. Tsubata A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, Akuta N, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H, Gastroenterol Hepatol 2005 20 426 432 10.1111/j.1440-1746.2004.03534.x (Pubitemid 40469345)
46. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg) -positive chronic hepatitis B. Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL, Antivir Ther 2008 13 571 579 18672536 (Pubitemid 352016720)
47. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. Marsden PA, Ning Q, Fung L, Luo X, Chen Y, Mendicino M, Ghanekar A, Scott JA, Miller T, Chan CW, Chan MW, He W, Gorczynski RM, Grant DR, Clark DA, Phillips MJ, Levy GA, J Clin Invest 2003 112 58 66 12840059 (Pubitemid 38056376)
48. Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. Zhu C, Sun Y, Luo X, Yan W, Xi D, Ning Q, Hum Gene Ther 2006 17 589 600 10.1089/hum.2006.17.589 16776568 (Pubitemid 43967863)
49. Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. Zhu CL, Yan WM, Zhu F, Zhu YF, Xi D, Tian DY, Levy G, Luo XP, Ning Q, World J Gastroenterol 2005 11 6936 6940 16437596 (Pubitemid 43126050)
50. Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway. Han M, Yan W, Guo W, Xi D, Zhou Y, Li W, Gao S, Liu M, Levy G, Luo X, Ning Q, J Biol Chem 2008 283 32715 32729 10.1074/jbc.M806769200 18801734